

Via Electronic filing

<b>RESPONSE TO RESTRICTION REQUIREMENT</b>  Address to: Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket No.	CHIR0006-101/P51716-US-PCT
	Confirmation No.	5426
	First Named Inventor	Kavanaugh, Michael W.
	Application Number	10/530,000
	Filing Date	June 19, 2007
	Group Art Unit	1648
	Examiner Name	Mosher, Mary
	Title:	"ANTI-CANCER AND ANTI-INFECTIOUS DISEASE COMPOSITIONS AND METHODS FOR USING SAME"

Sir:

This response is directed to the Communication dated September 8, 2010 for which a one-month period for response was given making this response due on or before October 8, 2010. As such, this response is timely filed.

In response to the Restriction Requirement, the Applicants elect to pursue Group I, claims 149-175, directed to a method of the prevention or treatment of a disease or a symptom thereof through the administration of a non-pathogenic insect-specific virus. This election is made without traverse.

Within the Group I election, the Applicants elect cancer.

For claim 155, the Applicants elect lung cancer.

For claim 157, the Applicants elect tumour growth.

For claim 163, the Applicants elect a viral particle.

For claim 168, the Applicants elect UV inactivation.

For claim 169, the Applicants elect a combination of Psoralen inactivation and UV inactivation.

For claim 170, the Applicants elect an anti-cancer drug.